Synopsis: In a recently issued final written decision, the Patent Trial and Appeal Board (the “Board”) found all challenged ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere ...

Your challenge this week? Take a hike! Whether it’s a rugged mountain trail, a peaceful local forest path, or even a city ...

Equities researchers at HC Wainwright issued their FY2029 EPS estimates for Atossa Therapeutics in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst E. Bodnar ...

Atossa Therapeutics (ATOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar ...

In a challenging market environment, Atossa Genetics Inc . (NASDAQ:ATOS) stock has touched a 52-week low, reaching a price ...

SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...

Atossa is also announcing the issuance of a new patent on January 21, 2025, U.S. Patent No. 12,201,591, entitled, “Sustained Release Compositions of Endoxifen.” The 31 claims of this new patent are ...

SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company with a market capitalization of $120 million and an impressive 13% gain over the past week, has announced ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...